Autoantibodies in Breast Cancer Detection

Inclusion Criteria:

- Inclusion Criteria:

All Cohorts:

- Women age 18 and older

- Understand and provide informed consent and HIPAA Authorization prior to initiation of
any study-specific procedures

Cohort A:

- Recent abnormal mammogram followed by a breast biopsy

- Initial diagnosis of Stage I, II, III or IV invasive breast cancer

Cohort B:

- Recent abnormal mammogram followed by a breast biopsy

- Diagnosed benign breast tumor with high-risk pathology. This would include, but is not
limited to, atypical ductal hyperplasia, atypical lobular hyperplasia, lobular
carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), flat epithelia atypia and
phylloides

Cohort C:

- Recent abnormal mammogram followed by a breast biopsy

- Diagnosed benign breast tumor. This would include, but is not limited to,
fibroadenoma, papilloma, fibrocystic changes, and Pseudoangiomatous stromal
hyperplasia (PASH)

Cohort D:

• Normal screening mammogram within the last 6 months

Exclusion Criteria:

- All Cohorts:

- Men.

- Unable or unwilling to give written informed consent

Cohort A:

• History of cancer other than non-melanoma basal or squamous cell skin carcinoma, ductal
carcinoma in situ (DCIS) and cervical carcinoma in situ.

Cohort B:

• History of cancer other than non-melanoma basal or squamous cell skin carcinoma and
cervical carcinoma in situ.

Cohort C:

• History of cancer other than non-melanoma basal or squamous cell skin carcinoma and
cervical carcinoma in situ.

Cohort D:

- History of cancer other than non-melanoma basal or squamous cell skin carcinoma and
cervical carcinoma in situ.

- History of or current autoimmune disease including but not limited to Sjogrens
Syndrome, Systemic Sclerosis (SSc), Scleroderma (Scl) and Dermatomyositis, Systemic
Lupus Erythematosus, Multiple Sclerosis, Type I Diabetes, Rheumatoid Arthritis

- History of abnormal mammogram